Journal of Clinical Oncology, Vol 16, 418-426, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer

CH Kohne, P Schoffski, H Wilke, C Kaufer, R Andreesen, U Ohl, U Klaasen, M Westerhausen, W Hiddemann, G Schott, A Harstick, J Bade, A Horster, U Schubert, H Hecker, B Dorken and HJ Schmoll
Department of Haematology/Oncology and Tumor Immunology, Robert-Rossle- Klinik, Berlin, Germany. koehne@rrk-berlin.de

PURPOSE: To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer. PATIENTS AND METHODS: Patients (n = 236) with progressive, measurable disease were randomized to three groups and received FU 2,600 mg/m2 as a 24- hour continuous infusion (CI) weekly for 6 weeks with 2 weeks rest (FU24h) and LV 500 mg/m2 as a 2-hour infusion before FU or IFN 3 x 10(6) U subcutaneously 3 times weekly or both. Treatment continued until progressive disease or unacceptable toxicity was observed. Pairs of treatment arms were analyzed sequentially to detect equivalence or a 25% difference in response rates. RESULTS: The rate of objective remission in patients who received FU24h/LV (44%; 40 of 91) was significantly higher than in patients who received FU24h/IFN (18%; 16 of 90; P < .05). The response rates of patients who received FU24h/LV versus FU24h/LV/IFN (27%; 13 of 49) were statistically equivalent. Significant differences were observed for time to tumor progression (TTP) (FU24h/LV, 7.1 months; FU24h/IFN, 3.9 months; FU24h/LV/IFN, 6.3 months; global P value < .009) and survival (16.6 months, 12.7 months, 19.6 months, respectively; global P value < .04). Unpredictable and life-threatening toxicity in the FU24h/LV/IFN arm required dose reduction of FU to 2,000 mg/m2/day and early stoppage of this arm. Toxicity was manageable in patients who received both FU24h/LV (grade 3 to 4 diarrhea, 21%) and FU24h/IFN (grade 3 to 4 diarrhea, 15%). CONCLUSION: Response rate, TTP, and overall survival were superior for LV-containing regimens compared with IFN modulation alone. The addition of IFN to high-dose infusional FU plus LV offers no advantage and may increase toxicity. The regimen of high-dose infusional FU24h/LV warrants further evaluation in patients with metastatic colorectal cancer.

This article has been cited by other articles:

				E. Aranda, M. Valladares, M. Martinez-Villacampa, M. Benavides, A. Gomez, B. Massutti, E. Marcuello, M. Constenla, J. C. Camara, A. Carrato, et al. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study Ann. Onc., August 20, 2008; (2008) mdn557v1. [Abstract] [Full Text] [PDF]

				M. Jacobson, A. J. O'Malley, C. C. Earle, J. Pakes, P. Gaccione, and J. P. Newhouse Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff., March 1, 2006; 25(2): 437 - 443. [Abstract] [Full Text] [PDF]

				C.-H. Kohne, E. van Cutsem, J. Wils, C. Bokemeyer, M. El-Serafi, M.P. Lutz, M. Lorenz, P. Reichardt, H. Ruckle-Lanz, N. Frickhofen, et al. Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986 J. Clin. Oncol., August 1, 2005; 23(22): 4856 - 4865. [Abstract] [Full Text] [PDF]

				C. D. Blanke Whither Irinotecan? J. Clin. Oncol., August 1, 2005; 23(22): 4811 - 4814. [Full Text] [PDF]

				A. Venook Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Oncologist, April 1, 2005; 10(4): 250 - 261. [Abstract] [Full Text] [PDF]

				The Meta-Analysis Group in Cancer Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis J. Clin. Oncol., September 15, 2004; 22(18): 3766 - 3775. [Abstract] [Full Text] [PDF]

				G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Ann. Onc., September 1, 2004; 15(9): 1330 - 1338. [Abstract] [Full Text] [PDF]

				E. Diaz-Rubio New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers Oncologist, June 1, 2004; 9(3): 282 - 294. [Abstract] [Full Text] [PDF]

				M. P. Goetz, C. Erlichman, A. J. Windebank, J. M. Reid, J. A. Sloan, P. Atherton, A. A. Adjei, J. Rubin, H. Pitot, E. Galanis, et al. Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3761 - 3769. [Abstract] [Full Text] [PDF]

				C-H. Kohne, J. Wils, M. Lorenz, P. Schoffski, R. Voigtmann, C. Bokemeyer, M. Lutz, U. Kleeberg, K. Ridwelski, R. Souchon, et al. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952 J. Clin. Oncol., October 15, 2003; 21(20): 3721 - 3728. [Abstract] [Full Text] [PDF]

				G. F. Fleming, R. L. Schilsky, L. P. Schumm, A. Meyerson, A. M. Hong, N. J. Vogelzang, and M. J. Ratain Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction Ann. Onc., July 1, 2003; 14(7): 1142 - 1147. [Abstract] [Full Text] [PDF]

				R. M. Goldberg, S. H. Kaufmann, P. Atherton, J. A. Sloan, A. A. Adjei, H. C. Pitot, S. R. Alberts, J. Rubin, L. L. Miller, and C. Erlichman A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin Ann. Onc., October 1, 2002; 13(10): 1674 - 1680. [Abstract] [Full Text] [PDF]

				J. Souglakos, D. Mavroudis, S. Kakolyris, Ch. Kourousis, N. Vardakis, N. Androulakis, S. Agelaki, K. Kalbakis, D. Tsetis, N. Athanasiadis, et al. Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial J. Clin. Oncol., June 1, 2002; 20(11): 2651 - 2657. [Abstract] [Full Text] [PDF]

				C.-H. Kohne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, et al. Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann. Onc., February 20, 2002; 13(2): 308 - 317. [Abstract] [Full Text] [PDF]

				P. J. O'Dwyer, J. Manola, F. H. Valone, L. M. Ryan, J. D. Hines, S. Wadler, D. G. Haller, S. G. Arbuck, L. M. Weiner, R. J. Mayer, et al. Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule--An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study J. Clin. Oncol., May 1, 2001; 19(9): 2413 - 2421. [Abstract] [Full Text] [PDF]

				L. B. Saltz, J.-Y. Douillard, N. Pirotta, M. Alakl, G. Gruia, L. Awad, G. L. Elfring, P. K. Locker, and L. L. Miller Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard Oncologist, February 1, 2001; 6(1): 81 - 91. [Abstract] [Full Text]

				J. L. Grem, N. Harold, J. Shapiro, D.-Q. Bi, M. G. Quinn, S. Zentko, B. Keith, J. M. Hamilton, B. P. Monahan, S. Donavan, et al. Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors J. Clin. Oncol., December 1, 2000; 18(23): 3952 - 3963. [Abstract] [Full Text] [PDF]

				J.-Y. Douillard Irinotecan: a new treatment in metastatic colorectal cancer Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S3 - S9. [Abstract] [PDF]

				A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer J. Clin. Oncol., August 16, 2000; 18(16): 2938 - 2947. [Abstract] [Full Text] [PDF]

				R.B. Arbuckle, S.L. Huber, and C. Zacker The Consequences of Diarrhea Occurring During Chemotherapy for Colorectal Cancer: A Retrospective Study Oncologist, June 1, 2000; 5(3): 250 - 259. [Abstract] [Full Text]

				S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail, R. Faggiuolo, C. Focan, P. Chollet, J. F. Llory, Y. Letourneau, B. Coudert, et al. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer J. Clin. Oncol., January 5, 2000; 18(1): 136 - 136. [Abstract] [Full Text] [PDF]

				T. Conroy and F. Guillemin Quality of Life in Advanced Colorectal Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1644 - 1644. [Full Text] [PDF]

				U. Vanhoefer, A. Harstrick, C.-H. Kohne, W. Achterrath, Y. M. Rustum, S. Seeber, and H. Wilke Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer J. Clin. Oncol., March 1, 1999; 17(3): 907 - 907. [Abstract] [Full Text] [PDF]